Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity
Journal of Virology · 23.12.2025 · 99 (12)
DOI: 10.1128/jvi.01256-25 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Virology, erschienen am 23.12.2025. Verfasst von Parker J Jamieson und 41 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: AIDS Vaccines, HIV Antibodies, HIV Infections, HIV-1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, NEI NIH HHS.
Abstract (Originalsprache)
HIV-1 continues to pose a significant global health challenge, requiring ongoing research into effective prevention and treatment strategies. Understanding the B-cell repertoire that can be engaged upon vaccination in humans is crucial for the development of future preventive vaccines. In this study, peripheral blood mononuclear cells from HIV-negative participants in the multivalent HVTN124 human HIV-1 vaccine clinical trial were interrogated for HIV-reactive B cells using LIBRA-seq, a high-throughput B-cell mapping technology. We report the discovery of glycan-reactive antibodies, with one of these being capable of neutralizing diverse heterologous HIV-1 virus strains. Furthermore, isolated antibodies showed broad cross-reactivity against antigens from a variety of other pathogens. The emerging class of glycan-reactive virus-neutralizing antibodies with exceptional breadth of pathogen cross-reactivity may present an effective target for vaccination at the population level. IMPORTANCE Understanding how the human immune system recognizes and combats viruses is crucial for developing better vaccines and treatments. Here, through characterization of the B-cell receptor repertoires of participants in HVTN124, a multivalent HIV-1 vaccine human clinical trial, we discovered antibodies that recognize sugar molecules (glycans) on antigens from a range of unrelated viral families. In addition to their binding breadth, these antibodies can also neutralize multiple diverse strains of HIV-1. Our findings reveal an emerging and underappreciated mechanism for antibodies to counteract virus infection, potentially opening doors for developing vaccines that preferentially elicit glycan-reactive antibody species to broadly protect against different viruses. This study is registered with ClinicalTrials.gov as NCT03409276 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt Center for Antibody Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
- Program in Chemical and Physical Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Integrative Immunobiology, Duke University School of Medicine, Durham, North Carolina, USA.
ORCID-Profile: Parker J Jamieson, Xiaoying Shen, Alexandra A Abu-Shmais, Simone I Richardson, Caroline A Alexander, James E Crowe, Barton F Haynes, Rachel H Bonami, Spyros A Kalams, Ivelin S Georgiev
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- NEI NIH HHS
- NIDDK NIH HHS
- NIH HHS
- NCRR NIH HHS
- NCI NIH HHS
- Wellcome Trust
Zitieren
APA
Jamieson, P. J., Shen, X., Abu-Shmais, A. A., Wasdin, P. T., Janowska, K., Edwards, R. J., Scapellato, G., Bukenya, M., Bass, L. E., Richardson, S. I., Manamela, N. P., Liu, S., Barr, M., Adams, L., Paola Velez-Castro, C., McCarthy, C., Alexander, C. A., Gillespie, R. A., Mimms, J., …, & Georgiev, I. S. (2025). Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity. Journal of Virology, 99(12). https://doi.org/10.1128/jvi.01256-25
Vancouver
Jamieson PJ, Shen X, Abu-Shmais AA, Wasdin PT, Janowska K, Edwards RJ, et al. Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity. Journal of Virology. 2025;99(12). doi:10.1128/jvi.01256-25
BibTeX
@article{Jamieson2025,
author = {Jamieson, Parker J and Shen, Xiaoying and Abu-Shmais, Alexandra A and Wasdin, Perry T and Janowska, Katarzyna and Edwards, Robert J and Scapellato, Garrett and Bukenya, Maurice and Bass, Lindsay E and Richardson, Simone I and Manamela, Nelia P and Liu, Shuying and Barr, Maggie and Adams, Lindsey and Paola Velez-Castro, Cristina and McCarthy, Caitlin and Alexander, Caroline A and Gillespie, Rebecca A and Mimms, Jessica and Suryadevara, Naveenchandra and Sornberger, Ty A and Zost, Seth J and Parks, Robert and Flaherty, Shelby and Janke, Alexis K and Howard, Bethany N and Suresh, Yukthi P and Ruprecht, Ruth M and Crowe, James E and Carnahan, Robert H and Bailey, Justin R and Kanekiyo, Masaru and Lingwood, Daniel and Haynes, Barton F and Moore, Penny L and Bonami, Rachel H and Tomaras, Georgia D and Archarya, Priyamvada and Montefiori, David C and Kalams, Spyros A and Lu, Shan and Georgiev, Ivelin S},
title = {Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity},
journal = {Journal of Virology},
year = {2025},
volume = {99},
number = {12},
doi = {10.1128/jvi.01256-25}
}
EUVIMED